Structure Therapeutics Inc. (GPCR) shareholders
Close on Nov 17, 2026Market cap $1.30BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| FMR LLC Joint filing with Abigail P. Johnson (15.00%) | 32,089,434 | 15.00% | 13G (passive) amendment | Sep 30, 2026 |
| Abigail P. Johnson Joint filing with FMR LLC (13.20%) | 28,197,369 | 13.20% | 13G (passive) amendment | Jun 30, 2026 |
| Wellington Investment Advisors Holdings LLP Joint filing with Wellington Management Group LLP (10.10%), Wellington Group Holdings LLP (10.10%) and 1 more | 21,365,952 | 10.10% | 13G (passive) amendment | Dec 31, 2025 |
| Wellington Group Holdings LLP Joint filing with Wellington Management Group LLP (11.90%), Wellington Investment Advisors Holdings LLP (11.90%) and 1 more | 20,631,498 | 11.90% | 13G (passive) amendment | Oct 31, 2025 |
| Wellington Management Group LLP Joint filing with Wellington Group Holdings LLP (9.90%), Wellington Investment Advisors Holdings LLP (9.90%) and 1 more | 17,067,561 | 9.90% | 13G (passive) amendment | Sep 30, 2025 |
| Avoro Capital Advisors LLC Joint filing with Aghazadeh Behzad (9.38%) | 16,216,665 | 9.38% | 13G (passive) | Sep 30, 2025 |
| Deep Track Biotechnology Master Fund, Ltd. Joint filing with Deep Track Capital, LP (8.92%), David Kroin (8.92%) | 15,401,751 | 8.92% | 13G (passive) amendment | Jun 30, 2025 |
| Deep Track Capital, LP Joint filing with Deep Track Biotechnology Master Fund, Ltd. (7.32%), David Kroin (7.32%) | 12,647,433 | 7.32% | 13G (passive) amendment | Sep 30, 2025 |
| David Kroin Joint filing with Deep Track Capital, LP (5.95%), Deep Track Biotechnology Master Fund, Ltd. (5.95%) | 12,335,346 | 5.95% | 13G (passive) amendment | Dec 31, 2025 |
| Lampert Mark N Joint filing with Bvf Partners L P/Il (5.60%), Bvf Inc/Il (5.60%) and 1 more | 9,611,751 | 5.60% | 13G (passive) | Aug 11, 2025 |
| Janus Henderson Group PLC | 4,448,826 | 7.70% | 13G (passive) amendment | Sep 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of GPCR | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 7,810,306 | 3.65% | $419.18M | −593,143 | 0.02% |
| Wellington Management Group Llp | 7,379,433 | 3.45% | $396.05M | +119,146 | 0.07% |
| Avoro Capital Advisors LLC | 6,555,555 | 3.06% | $351.84M | – | 3.16% |
| Jupiter Topco LLC | 5,204,212 | 2.43% | $279.34M | New | 0.11% |
| Deep Track Capital, LP | 4,740,072 | 2.22% | $254.40M | +460,224 | 3.70% |
| Bvf Inc/Il | 3,366,823 | 1.57% | $180.70M | −92,535 | 4.62% |
| Morgan Stanley | 2,806,640 | 1.31% | $150.63M | +501,183 | 0.01% |
| Orbimed Advisors LLC | 2,209,400 | 1.03% | $118.58M | +733,997 | 2.20% |
| Principal Financial Group Inc | 1,752,753 | 0.82% | $94.07M | −1,011 | 0.05% |
| American Century Companies Inc | 1,682,179 | 0.79% | $90.28M | +244,148 | 0.04% |
| Rtw Investments, LP | 1,607,507 | 0.75% | $86.27M | New | 0.74% |
| Driehaus Capital Management LLC | 1,553,219 | 0.73% | $83.36M | −24,137 | 0.48% |
| Baker Bros. Advisors LP | 1,432,529 | 0.67% | $76.88M | – | 0.39% |
| Casdin Capital, LLC | 1,175,000 | 0.55% | $63.06M | – | 3.16% |
| Deerfield Management Company, L.P. (Series C) | 1,086,000 | 0.51% | $58.29M | +318,007 | 0.61% |
| Capitolis Liquid Global Markets LLC | 1,041,100 | 0.49% | $55.88M | −110,200 | 0.24% |
| Siren, L.L.C. | 872,967 | 0.41% | $46.85M | −455,731 | 0.95% |
| Price T Rowe Associates Inc /Md/ | 845,532 | 0.40% | $45.38M | −1,155,164 | 0.00% |
| Pacific Heights Asset Management LLC | 800,000 | 0.37% | $42.94M | +50,000 | 1.36% |
| Rock Springs Capital Management LP | 640,317 | 0.30% | $34.37M | +100 | 1.68% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 192 | 68M | 31.6% | 29 / 76 | 51 / 31 | 12M | 6M |
| Q1 2026 | 196 | 67M | 31.3% | 40 / 73 | 57 / 39 | 8M | 6M |
| Q4 2025 | 197 | 66M | 30.8% | 71 / 52 | 62 / 27 | 20M | 11M |
| Q3 2025 | 156 | 57M | 26.5% | 22 / 57 | 49 / 37 | 13M | 11M |
| Q2 2025 | 172 | 55M | 25.6% | 38 / 63 | 44 / 16 | 9M | 10M |
| Q1 2025 | 150 | 56M | 26.2% | 23 / 47 | 50 / 36 | 4M | 9M |
| Q4 2024 | 164 | 61M | 28.4% | 29 / 64 | 50 / 23 | 8M | 9M |
| Q3 2024 | 160 | 62M | 28.8% | 28 / 68 | 35 / 33 | 9M | 7M |
| Q2 2024 | 166 | 60M | 28.2% | 61 / 63 | 33 / 13 | 23M | 7M |
| Q1 2024 | 119 | 44M | 20.7% | 25 / 45 | 35 / 26 | 9M | 8M |
| Q4 2023 | 121 | 43M | 20.0% | 54 / 36 | 25 / 17 | 19M | 9M |
| Q3 2023 | 84 | 33M | 15.3% | 42 / 29 | 6 / 6 | 17M | 2M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
141 funds held GPCR in Q2 2026, 4% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of GPCR | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Health Care Fund | 3,278,237 | 1.53% | $157.49M | 0.41% | Jul 31, 2026 |
| Heritage Fund | 967,353 | 0.45% | $46.47M | 0.87% | Jul 31, 2026 |
| Fidelity Advisor Growth Opportunities Fund | 733,500 | 0.34% | $28.86M | 0.08% | May 31, 2026 |
| Global Emerging Markets Fund | 625,751 | 0.29% | $30.06M | 0.40% | Jul 31, 2026 |
| Janus Henderson Global Life Sciences Fund | 549,353 | 0.26% | $29.48M | 0.51% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 542,038 | 0.25% | $21.32M | 0.40% | May 31, 2026 |
| Select Health Care Portfolio | 540,000 | 0.25% | $21.24M | 0.37% | May 31, 2026 |
| Fidelity Advisor Biotechnology Fund | 527,900 | 0.25% | $25.36M | 1.15% | Jul 31, 2026 |
| Janus Henderson Triton Fund | 467,112 | 0.22% | $25.07M | 0.42% | Jun 30, 2026 |
| Fidelity Stock Selector Small Cap Fund | 433,100 | 0.20% | $20.81M | 0.28% | Jul 31, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 419,407 | 0.20% | $22.51M | 0.19% | Jun 30, 2026 |
| Fidelity Small Cap Growth Fund | 414,389 | 0.19% | $19.91M | 0.23% | Jul 31, 2026 |
| iShares Biotechnology ETF | 414,261 | 0.19% | $22.23M | 0.24% | Jun 30, 2026 |
| Vanguard Explorer Fund | 405,606 | 0.19% | $19.49M | 0.09% | Jul 31, 2026 |
| Permanent Portfolio | 400,000 | 0.19% | $19.22M | 0.27% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Raymond C. Stevens | CHIEF EXECUTIVE OFFICER, Director | 2,956,179 | 1.38% | Mar 23, 2026 |
| Crespo Blas Coll | CHIEF MEDICAL OFFICER | 258,228 | 0.12% | Sep 22, 2026 |
| Xichen Lin | CHIEF SCIENTIFIC OFFICER | 228,960 | 0.11% | Sep 2, 2026 |
| John Joseph Berrios | Chief Commercial Officer | 140,766 | 0.07% | Aug 7, 2026 |
| Matthew Lang | COO & GC | 184,614 | 0.09% | Apr 23, 2026 |
| Jun Yoon | CHIEF FINANCIAL OFFICER | 2,956,242 | 1.38% | Mar 23, 2026 |
| Yingli Ma | CHIEF TECHNOLOGY OFFICER | 139,917 | 0.07% | Mar 23, 2026 |
| Ashley Hall | Chief Development Officer | 155,187 | 0.07% | Mar 23, 2026 |
| Eric Dobmeier | Director | – | – | Jun 18, 2026 |
| Angus C. Russell | Director | – | – | Jun 18, 2026 |
| Ted W. Love | Director | – | – | Jun 18, 2026 |
| Daniel G. Welch | Director | 123,508 | 0.06% | Jun 18, 2026 |
| Sharon Tetlow | Director | – | – | Jun 18, 2026 |
| Joanne Waldstreicher | Director | – | – | Jun 18, 2026 |
| Llc Fmr | 10% owner | 261,777 | 0.12% | Jul 24, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Crespo Blas Coll CHIEF MEDICAL OFFICER | Sep 21, 2026 | Conversion | −12,024 | – | – | 258,228 |
| Crespo Blas Coll CHIEF MEDICAL OFFICER | Sep 18, 2026 | Tax withholding | −10,626 | $11.67 | $124.01K | 270,252 |
| Xichen Lin CHIEF SCIENTIFIC OFFICER | Sep 1, 2026 | Conversion | −17,817 | – | – | 228,960 |
| Xichen Lin CHIEF SCIENTIFIC OFFICER | Sep 1, 2026 | Option exercise | +17,817 | $0.34 | $6.06K | 246,777 |
| Xichen Lin CHIEF SCIENTIFIC OFFICER | Aug 18, 2026 | Option exercise | +11,817 | $0.34 | $4.02K | 240,777 |
| Xichen Lin CHIEF SCIENTIFIC OFFICER | Aug 18, 2026 | Conversion | −11,817 | – | – | 228,960 |
| John Joseph Berrios Chief Commercial Officer | Aug 6, 2026 | Award | +140,766 | – | – | 140,766 |
| Xichen Lin CHIEF SCIENTIFIC OFFICER | Aug 4, 2026 | Conversion | −11,817 | – | – | 228,960 |
| Xichen Lin CHIEF SCIENTIFIC OFFICER | Aug 4, 2026 | Option exercise | +11,817 | $0.34 | $4.02K | 240,777 |
| Xichen Lin CHIEF SCIENTIFIC OFFICER | Jul 14, 2026 | Conversion | −23,634 | – | – | 228,960 |
| Xichen Lin CHIEF SCIENTIFIC OFFICER | Jul 14, 2026 | Option exercise | +23,634 | $0.34 | $8.04K | 252,594 |
| Xichen Lin CHIEF SCIENTIFIC OFFICER | Jun 25, 2026 | Conversion | −23,634 | – | – | 228,960 |
| Xichen Lin CHIEF SCIENTIFIC OFFICER | Jun 25, 2026 | Option exercise | +23,634 | $0.34 | $8.04K | 252,594 |
| Matthew Lang COO & GC | Apr 15, 2026 | Award | +184,614 | – | – | 184,614 |
| Yingli Ma CHIEF TECHNOLOGY OFFICER | Mar 19, 2026 | Award | +32,526 | – | – | 139,917 |
| Xichen Lin CHIEF SCIENTIFIC OFFICER | Mar 19, 2026 | Award | +43,368 | – | – | 228,960 |
| Raymond C. Stevens CHIEF EXECUTIVE OFFICER, Director | Mar 19, 2026 | Award | +260,217 | – | – | 1,401,593 |
| Crespo Blas Coll CHIEF MEDICAL OFFICER | Mar 19, 2026 | Award | +75,897 | – | – | 280,878 |
| Ashley Hall Chief Development Officer | Mar 19, 2026 | Award | +47,706 | – | – | 155,187 |
| Jun Yoon CHIEF FINANCIAL OFFICER | Mar 19, 2026 | Award | +104,085 | – | – | 1,401,656 |
| Raymond C. Stevens CHIEF EXECUTIVE OFFICER, Director | Mar 3, 2026 | Tax withholding | −53,454 | $20.99 | $1.12M | 1,141,376 |
| Xichen Lin CHIEF SCIENTIFIC OFFICER | Mar 3, 2026 | Tax withholding | −18,735 | $20.99 | $393.25K | 185,592 |
| Jun Yoon CHIEF FINANCIAL OFFICER | Mar 3, 2026 | Tax withholding | −22,305 | $20.99 | $468.18K | 1,297,571 |
| Crespo Blas Coll CHIEF MEDICAL OFFICER | Mar 3, 2026 | Tax withholding | −11,826 | $20.99 | $248.23K | 204,981 |
| Ashley Hall Chief Development Officer | Mar 3, 2026 | Tax withholding | −4,836 | $20.99 | $101.51K | 107,481 |
| Yingli Ma CHIEF TECHNOLOGY OFFICER | Mar 3, 2026 | Tax withholding | −11,313 | $20.99 | $237.46K | 107,391 |
| Crespo Blas Coll CHIEF MEDICAL OFFICER | Sep 18, 2025 | Tax withholding | −8,106 | $7.74 | $62.74K | 216,807 |
| Ashley Hall Chief Development Officer | Sep 18, 2025 | Tax withholding | −6,021 | $7.74 | $46.60K | 112,317 |
| Yingli Ma CHIEF TECHNOLOGY OFFICER | Jul 1, 2025 | Tax withholding | −4,470 | $6.84 | $30.57K | 118,704 |
| Xichen Lin CHIEF SCIENTIFIC OFFICER | Jul 1, 2025 | Tax withholding | −12,846 | $6.84 | $87.87K | 204,327 |
| Yingli Ma CHIEF TECHNOLOGY OFFICER | Jul 1, 2025 | Award | +24,459 | – | – | 123,174 |
| Crespo Blas Coll CHIEF MEDICAL OFFICER | Jul 1, 2025 | Tax withholding | −1,434 | $6.84 | $9.81K | 224,913 |
| Crespo Blas Coll CHIEF MEDICAL OFFICER | Jul 1, 2025 | Award | +7,992 | – | – | 226,347 |
| Xichen Lin CHIEF SCIENTIFIC OFFICER | Jul 1, 2025 | Award | +57,078 | – | – | 217,173 |
| Raymond C. Stevens CHIEF EXECUTIVE OFFICER, Director | Jul 1, 2025 | Award | +89,697 | – | – | 1,210,880 |
| Raymond C. Stevens CHIEF EXECUTIVE OFFICER, Director | Jul 1, 2025 | Tax withholding | −16,050 | $6.84 | $109.78K | 1,194,830 |
| Jun Yoon CHIEF FINANCIAL OFFICER | Jul 1, 2025 | Tax withholding | −7,089 | $6.84 | $48.49K | 1,319,876 |
| Jun Yoon CHIEF FINANCIAL OFFICER | Jul 1, 2025 | Award | +39,606 | – | – | 1,326,965 |
| Ashley Hall Chief Development Officer | Mar 15, 2025 | Award | +51,048 | – | – | 118,338 |
| Raymond C. Stevens CHIEF EXECUTIVE OFFICER, Director | Mar 15, 2025 | Award | +340,332 | – | – | 1,133,678 |
| Yingli Ma CHIEF TECHNOLOGY OFFICER | Mar 15, 2025 | Award | +63,810 | – | – | 100,539 |
| Crespo Blas Coll Chief Medical Officer | Mar 15, 2025 | Award | +116,988 | – | – | 219,588 |
| Xichen Lin CHIEF SCIENTIFIC OFFICER | Mar 15, 2025 | Award | +80,829 | – | – | 166,536 |
| Jun Yoon CHIEF FINANCIAL OFFICER | Mar 15, 2025 | Award | +170,166 | – | – | 1,293,299 |
| Yingli Ma CHIEF TECHNOLOGY OFFICER | Mar 1, 2025 | Tax withholding | −1,824 | $7.92 | $14.45K | 98,715 |
| Crespo Blas Coll CHIEF MEDICAL OFFICER | Mar 1, 2025 | Tax withholding | −1,233 | $7.92 | $9.77K | 218,355 |
| Xichen Lin CHIEF SCIENTIFIC OFFICER | Mar 1, 2025 | Tax withholding | −6,441 | $7.92 | $51.01K | 160,095 |
| Raymond C. Stevens CHIEF EXECUTIVE OFFICER, Director | Mar 1, 2025 | Tax withholding | −12,495 | $7.92 | $98.96K | 1,121,183 |
| Jun Yoon CHIEF FINANCIAL OFFICER | Mar 1, 2025 | Tax withholding | −5,940 | $7.92 | $47.04K | 1,287,359 |
| Crespo Blas Coll Chief Medical Officer | Sep 18, 2024 | Award | +90,600 | – | – | 102,600 |
| Ashley Hall Chief Development Officer | Sep 18, 2024 | Award | +67,290 | – | – | 67,290 |
| Raymond C. Stevens CHIEF EXECUTIVE OFFICER, Director | Jun 12, 2024 | Option exercise | +99,999 | $0.39 | $39.00K | 743,345 |
| Raymond C. Stevens CHIEF EXECUTIVE OFFICER, Director | Jun 12, 2024 | Option exercise | +50,001 | $0.48 | $24.00K | 793,346 |
| Raymond C. Stevens CHIEF EXECUTIVE OFFICER, Director | Jun 10, 2024 | Conversion | −555,000 | – | – | 643,346 |
| Xichen Lin CHIEF SCIENTIFIC OFFICER | Jun 3, 2024 | Conversion | −106,200 | – | – | 85,707 |
| Xichen Lin CHIEF SCIENTIFIC OFFICER | Jun 3, 2024 | Option exercise | +106,200 | $0.34 | $36.11K | 191,907 |
| Mark Allen Bach CHIEF MEDICAL OFFICER | Mar 15, 2024 | Award | +26,235 | – | – | 26,235 |
| Raymond C. Stevens CHIEF EXECUTIVE OFFICER, Director | Mar 15, 2024 | Award | +134,682 | – | – | 1,198,346 |
| Xichen Lin CHIEF SCIENTIFIC OFFICER | Mar 15, 2024 | Award | +85,707 | – | – | 85,707 |
| Jun Yoon CHIEF FINANCIAL OFFICER | Mar 15, 2024 | Award | +59,469 | – | – | 1,123,133 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Structure Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 9,578 shares on Oct 1, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Crespo Blas Coll Officer | Sep 21, 2026 | 4,008 | $140.28K | Sep 21, 2026 | Restricted Stock Units |
| Xichen Lin Officer | Jun 25, 2026 | 35,512 | $1.71M | Jun 25, 2026 | Exercise of Stock Options |
| Raymond C. Stevens Officer | Jun 10, 2024 | 185,000 | $9.77M | Jun 10, 2024 | Founder Stock |
| Xichen Lin Officer | Jun 3, 2024 | 59,000 | $2.02M | Jun 3, 2024 | Exercise of Stock Options |
See a number that looks wrong?